Skip to content
DataLookout
Menu

NAVIGATE-2NCT07225959

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words
    • Trial sites reduced: 6 → 3 locations
    • Secondary endpoints: details revised at 4 of 6 entries
  2. Notable Primary endpoint(s) modifiedv4 Show 7 more changesShow less
    • Eligibility criteria shortened, about 981 words
    • Trial sites expanded: 3 → 6 locations
    • Primary and study completion dates: Jul 2027 to Jul 31, 2027
    • Interventions: CD388 Injection (Combination Product) to MK-1406 Injection (Combination Product)
    • Secondary endpoints revised (6)
    • Study title shortened, about 6 words
    • Study description expanded, about 1 word
  3. Notable Changed Sponsor changed: Cidara Therapeutics Inc. to Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v3
  5. Minor Site details revised at 1 of 3 sitesv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Treatment-Induced Anti-Drug Antibodies (ADAs)
Timeframe: Periods 1 and 2: Day 1, Day 29, Day 85, Day 169, and Day 197
Number of Participants with Treatment-Boosted ADAs
Timeframe: Periods 1 and 2: Day 1, Day 29, Day 85, Day 169, and Day 197

Secondary (6)

Number of participants with ≥1 Adverse Event (AE)
Number of Participants Who Discontinued from the Study Due to an AE
Number of Participants with a Solicited Injection-site AE
Number of Participants with a Serious Adverse Event (SAE)
Plasma Concentration Following Administration of MK-1406
Show 1 moreShow less
Plasma concentration of MK-1406 by anti-drug antibody (ADA) status.

Arms and interventions

MK-1406Experimental

Participant will receive 450 mg dose of MK-1406 (CD388) by subcutaneous (SC) injection followed 1 year later by a repeat single 450 mg dose of MK-1406 administered by SC injection.

Combination products: MK-1406 Injection

Sites

3 sites in 2 countries

United States 2, United Kingdom 1